A recent OncLive article looks at how the COVID-19 pandemic is shaping real-world data initiatives in the oncology landscape.
The Food and Drug Administration (FDA) is in the process of modifying how RWD is used in cancer care, according to the article.
“We now find ourselves in a grand experiment,” FDA Oncology Center of Excellence Deputy Director Paul Kluetz tells OncLive. “By necessity, COVID-19 has pushed the cancer clinical trial community out of its comfort zone to rapidly deploy remote assessments and digital health technology, [prompting] unprecedented collaboration to explore the use of real-world data.”
To read the full report on OncLive, click here.
